LivingGLP1
Study S001933

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6 - Long-term Outcomes)

Included trial: extracted dataClinicalTrials.gov record

Registration

Registration
NCT01720446
Acronym
SUSTAIN™ 6
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE3
Masking
DOUBLE
Status
COMPLETED
Enrollment
3297
Start
2013-02-21
Primary completion
2016-03-15
Lead sponsor
Novo Nordisk A/S
Conditions
Diabetes; Diabetes Mellitus, Type 2
Interventions
DRUG:semaglutide; DRUG:placebo
Results posted
TRUE
Secondary identifiers
EUDRACT_NUMBER:2012-002839-28; OTHER:U1111-1131-7227

Registered primary outcomes

  • Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke [Time from randomisation up to end of follow-up (scheduled at week 109)]

Linked records (40)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0003175Semaglutide and Cardiovascular Outcomes in People with Type 2 Diabetes: A SUSTAIN-6 Post Hoc Analysis by Weight Loss Category.
Navas A, Diabetes therapy : research, treatment and education of diabetes and related disorders
2026Randomized trialPMID 42105046DOIcites ClinicalTrials.gov:NCT01720446
R00385031775-P: Effect of Subcutaneous Semaglutide on Cardiorenal Outcomes across Type 2 Diabetes Subtypes: SUSTAIN 6 Post Hoc Analysis
WEIHAO WANG, Diabetes
2026OtherDOIcites ClinicalTrials.gov:NCT01720446
R0010237Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.
Natale P, The Cochrane database of systematic reviews
2025Systematic reviewPMID 39963952DOIcites ClinicalTrials.gov:NCT01720446; registry reference DERIVED:39963952
R0016776Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6.
Zhou J, Diabetes, obesity & metabolism
2025Other trialPMID 40704485DOIcites ClinicalTrials.gov:NCT01720446
R0018274Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6.
Bain SC, Diabetes therapy : research, treatment and education of diabetes and related disorders
2025Other trialPMID 39520501DOIcites ClinicalTrials.gov:NCT01720446; registry reference DERIVED:39520501
R0042126Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomised SUSTAIN 6 & PIONEER 6
WD Strain (14423826), Figshare
2025Randomized trialcites ClinicalTrials.gov:NCT01720446
R0006532Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial.
Tuttle KR, Kidney international reports
2024Other trialPMID 39081763DOIcites ClinicalTrials.gov:NCT01720446
R0020454Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials.
Mellbin LG, European heart journal
2024Nonrandomized studyPMID 38416593DOIcites ClinicalTrials.gov:NCT01720446
R0021172Once-weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis.
Kobo O, Diabetes, obesity & metabolism
2024Randomized trialPMID 38082468DOIcites ClinicalTrials.gov:NCT01720446
R0039098Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
Rossing, Peter, Figshare
2024Other trialDOIcites ClinicalTrials.gov:NCT01720446
R0020475Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.
Rossing P, Cardiovascular diabetology
2023Other trialPMID 37620807DOIcites ClinicalTrials.gov:NCT01720446; registry reference DERIVED:37620807
R0022330Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials.
Verma S, Diabetes, obesity & metabolism
2023Randomized trialPMID 37016488DOIcites ClinicalTrials.gov:NCT01720446
R0052091#4441 KIDNEY DISEASE OUTCOMES WITH SEMAGLUTIDE VERSUS PLACEBO ACROSS BASELINE KDIGO RISK CATEGORIES: A POST HOC ANALYSIS OF SUSTAIN 6
Katherine R. Tuttle, Nephrology Dialysis Transplantation
2023Randomized trialDOIcites ClinicalTrials.gov:NCT01720446
R0007143Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.
Husain M, Cardiovascular diabetology
2022Systematic reviewPMID 35484580DOIcites ClinicalTrials.gov:NCT01720446; registry reference DERIVED:35484580
R0010495Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6.
Strain WD, Stroke
2022Randomized trialPMID 35582947DOIcites ClinicalTrials.gov:NCT01720446; registry reference DERIVED:35582947
R0016413Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.
Verma S, Diabetes, obesity & metabolism
2022OtherPMID 35332654DOIcites ClinicalTrials.gov:NCT01720446; registry reference DERIVED:35332654
R0053166MO462: Change in KDIGO Kidney Risk Category With Semaglutide Treatment—A Post Hoc Analysis of the Sustain 6 Trial
Katherine R. Tuttle, Nephrology Dialysis Transplantation
2022Randomized trialDOIcites ClinicalTrials.gov:NCT01720446
R0020208Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide.
Verma S, Diabetes, obesity & metabolism
2021Other trialPMID 33606902DOIcites ClinicalTrials.gov:NCT01720446; registry reference DERIVED:33606902
R0047600FC 058THE IMPORTANCE OF ADDRESSING MULTIPLE RISK MARKERS IN TYPE 2 DIABETES: RESULTS FROM THE LEADER AND SUSTAIN 6 TRIALS
Emilie H. Zobel, Nephrology Dialysis Transplantation
2021Randomized trialDOIcites ClinicalTrials.gov:NCT01720446
R0006154Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.
Verma S, Diabetes, obesity & metabolism
2020Randomized trialPMID 32744418DOIcites ClinicalTrials.gov:NCT01720446; registry reference DERIVED:32744418
R0006812The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.
Leiter LA, Diabetes, obesity & metabolism
2020OtherPMID 32372454DOIcites ClinicalTrials.gov:NCT01720446; registry reference DERIVED:32372454
R0015927Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials.
DeSouza C, The Journal of clinical endocrinology and metabolism
2020Randomized trialPMID 31769496DOIcites ClinicalTrials.gov:NCT01720446; registry reference DERIVED:31769496
R0018529Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
Husain M, Cardiovascular diabetology
2020Randomized trialPMID 32998732DOIcites ClinicalTrials.gov:NCT01720446; registry reference DERIVED:32998732
R0018857Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
Husain M, Diabetes, obesity & metabolism
2020OtherPMID 31903692DOIcites ClinicalTrials.gov:NCT01720446; registry reference DERIVED:31903692
R0019976Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials.
Verma S, Diabetes, obesity & metabolism
2020Randomized trialPMID 32643857DOIcites ClinicalTrials.gov:NCT01720446; registry reference DERIVED:32643857
R0024109Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6).
Jódar E, Diabetes, obesity & metabolism
2020Other trialPMID 32227613DOIcites ClinicalTrials.gov:NCT01720446; registry reference DERIVED:32227613
R0041631APPLYING REWIND CVD CRITERIA TO SUSTAIN 6 AND PIONEER 6: AN EXPLORATORY ANALYSIS OF CV OUTCOMES WITH SEMAGLUTIDE
Subodh Verma, Journal of the American College of Cardiology
2020Other trialDOIcites ClinicalTrials.gov:NCT01720446
R0047322Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials
Maria Sejersten Ripa, Carolina Digital Repository (University of North Carolina at Chapel Hill)
2020Randomized trialDOIcites ClinicalTrials.gov:NCT01720446
R0048083Estimating cardiovascular disease-free life-years with the addition of semaglutide in people with type 2 diabetes using pooled data from SUSTAIN 6 and PIONEER 6
Jan Westerink, European Heart Journal
2020Randomized trialDOIcites ClinicalTrials.gov:NCT01720446
R0049018Abstract 13814: Semaglutide Reduces Mace Consistently Across Baseline Triglyceride Levels in Patients With Type 2 Diabetes: A Post Hoc Analysis of the Sustain 6 and Pioneer 6 Trials
Subodh Verma, Circulation
2020Randomized trialDOIcites ClinicalTrials.gov:NCT01720446
R0049459Effects of liraglutide and semaglutide on stroke subtypes in patients with type 2 diabetes: a post hoc analysis of the LEADER, SUSTAIN 6 and PIONEER 6 trials
William David Strain, European Heart Journal
2020Randomized trialDOIcites ClinicalTrials.gov:NCT01720446
R0053890Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials
J.B. Buse, Carolina Digital Repository (University of North Carolina at Chapel Hill)
2020Other trialDOIcites ClinicalTrials.gov:NCT01720446
R0013158Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
Aroda VR, Diabetes & metabolism
2019Other trialPMID 30615985DOIregistry reference RESULT:30615985
R0017025Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.
Verma S, Diabetes, obesity & metabolism
2019Other trialPMID 30851070DOIcites ClinicalTrials.gov:NCT01720446; registry reference BACKGROUND:30851070
R0025777Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.
Leiter LA, Cardiovascular diabetology
2019Nonrandomized studyPMID 31167654DOIcites ClinicalTrials.gov:NCT01720446; registry reference RESULT:31167654
R0007117Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population.
Wittbrodt ET, The American journal of managed care
2018Nonrandomized studyPMID 29693361cites ClinicalTrials.gov:NCT01720446; registry reference DERIVED:29693361
R0013229Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis.
Carlsson Petri KC, Diabetes therapy : research, treatment and education of diabetes and related disorders
2018Other trialPMID 29907893DOIcites ClinicalTrials.gov:NCT01720446; registry reference RESULT:29907893
R0020578Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.
Vilsbøll T, Diabetes, obesity & metabolism
2018Other trialPMID 29178519DOIregistry reference RESULT:29178519
R0049736Implications of cardiovascular outcome trials with injectable antidiabetic agents
Richard E. Pratley, Journal of Diabetes
2018Randomized trialPMID 29971941DOIcites ClinicalTrials.gov:NCT01720446
R0022278Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, The New England journal of medicine
2016Randomized trialPMID 27633186DOIcites ClinicalTrials.gov:NCT01720446; registry reference RESULT:27633186